Evidence map›Paper›PMID 29522576›Full record

ArticlePloS one2018

Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Kota Asakura, Takuya Azechi, Hiroshi Sasano, Hidehito Matsui, Hideaki Hanaki, Motoyasu Miyazaki, Tohru Takata, Miwa Sekine, Tomoiku Takaku, Tomonori Ochiai and 4 more

Abstract readMulticenter Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kota AsakuraDepartment of Pharmacy, Juntendo University Hospital, Tokyo, Japan.
Takuya AzechiDepartment of Pharmacy, Juntendo University Hospital, Tokyo, Japan.
Hiroshi SasanoDepartment of Pharmacy, Juntendo University Hospital, Tokyo, Japan.
Hidehito MatsuiInfection Control Research Center, Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan.
Hideaki HanakiInfection Control Research Center, Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan.
Motoyasu MiyazakiDepartment of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka, Japan.
Tohru TakataDepartment of Infection Control, Fukuoka University Hospital, Fukuoka, Japan.
Miwa SekineDepartment of Microbiology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Tomoiku TakakuDivision of Hematology, Department of Internal Medicine, Juntendo University, Tokyo, Japan.
Tomonori OchiaiDivision of Hematology, Department of Internal Medicine, Juntendo University, Tokyo, Japan.
Norio KomatsuDivision of Hematology, Department of Internal Medicine, Juntendo University, Tokyo, Japan.
Keigo ShibayamaDepartment of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.
Yuki KatayamaDepartment of Microbiology, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Koji YaharaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0003-4289-1115

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vancomycin-intermediately resistant Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) are associated with treatment failure. hVISA contains only a subpopulation of cells with increased minimal inhibitory concentrations, and its detection is problematic because it is classified as vancomycin-susceptible by standard susceptibility testing and the gold-standard method for its detection is impractical in clinical microbiology laboratories. Recently, a research group developed a machine-learning classifier to distinguish VISA and hVISA from vancomycin-susceptible S. aureus (VSSA) according to matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) data. Nonetheless, the sensitivity of hVISA classification was found to be 76%, and the program was not completely automated with a graphical user interface. Here, we developed a more accurate machine-learning classifier for discrimination of hVISA from VSSA and VISA among MRSA isolates in Japanese hospitals by means of MALDI-TOF MS data. The classifier showed 99% sensitivity of hVISA classification. Furthermore, we clarified the procedures for preparing samples and obtaining MALDI-TOF MS data and developed all-in-one software, hVISA Classifier, with a graphical user interface that automates the classification and is easy for medical workers to use; it is publicly available at https://github.com/bioprojects/hVISAclassifier. This system is useful and practical for screening MRSA isolates for the hVISA phenotype in clinical microbiology laboratories and thus should improve treatment of MRSA infections.

Indexed as

Drug Resistance, BacterialSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAnti-Bacterial AgentsHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsSoftwareStaphylococcal InfectionsVancomycinAnti-Bacterial AgentsVancomycin

Identifiers

PMID29522576
PMCPMC5844673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.